Financial Contrast: Connect Biopharma (NASDAQ:CNTB) & GRAIL (NASDAQ:GRAL)

Connect Biopharma (NASDAQ:CNTB) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Institutional & Insider Ownership

58.7% of Connect Biopharma shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 1.8% of GRAIL shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Connect Biopharma and GRAIL’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-165.41%	-121.58%
GRAIL	-236.95%	-15.88%	-14.02%

Valuation & Earnings

This table compares Connect Biopharma and GRAIL”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60,000.00	764.77	-$55.48 million	($1.19)	-0.61
GRAIL	$147.17 million	36.86	-$408.35 million	($9.50)	-12.78

Connect Biopharma has higher earnings, but lower revenue than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Connect Biopharma has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500. Comparatively, GRAIL has a beta of 2.86, indicating that its stock price is 186% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Connect Biopharma and GRAIL, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1	0	8	0	2.78
GRAIL	1	6	5	0	2.33

Connect Biopharma presently has a consensus target price of $5.88, indicating a potential upside of 706.23%. GRAIL has a consensus target price of $121.40, indicating a potential downside of 0.03%. Given Connect Biopharma’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Connect Biopharma is more favorable than GRAIL.

Summary

Connect Biopharma beats GRAIL on 10 of the 14 factors compared between the two stocks.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

About GRAIL

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.